Jacobio Pharmaceuticals (HKG:1167) received approval from China's National Medical Products Administration for glecirasib to be launched on the market, a Thursday Hong Kong bourse filing said.
The approved indication is for patients with non-small cell lung cancer harboring KRAS G12C mutations who have received at least one prior systemic therapy.
The approval will trigger a 50 million yuan milestone payment to the pharmaceutical company from partner Shanghai Allist Pharmaceuticals (SHA:688578).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.